Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)

Alireza M. Manuchehri, Thozhukat Sathyapalan, Martin Lowry, Lindsay W. Turnbull, Christopher Rowland-Hill, Stephen Atkin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Context: Dopamine agonists (DA) may act on prolactinoma size and secretion through additional effects on adenoma vascularity that can be visualized using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Objective: We hypothesized that DAs may exert their effect through a change in tumour functional vascularity leading to a reduction of prolactin (PRL) levels and tumour size. Subjects and methods: To investigate this, 23 subjects were studied comprising five with macroprolactinomas, 11 with microprolactinomas, seven with non-lesion hyperprolactinemia and 15 normal volunteers (including five females on oral contraceptive pills). Patients with macroprolactinomas were treated with cabergoline 4 mg weekly and microprolactinomas were treated with quinagolide 75 μg daily for the duration of study. DCE-MRI was performed immediately pre-treatment and at 3-4 days, 1 and 3-4 months after treatment. Normal volunteers took three 75 μg quinagolide doses and were scanned pre-treatment and at 3 days. Data were analysed using the Brix model, producing a measure of vascular permeability and leakage space. Results: PRL levels were significantly reduced in all patients and volunteers. Vascular parameters decreased significantly for four of five macroprolactinomas and all microprolactinomas which were maintained during the treatment period (p < 0.01). No changes were seen in normal volunteers or non-lesion hyperprolactinemia. One of five macroprolactinomas showed no change in either permeability or tumour size. Conclusion: Functional prolactinoma vascularity differs from non-lesion hyperprolactinemic pituitary and normal pituitary, and is responsive to DA therapy. The reduction in vascular parameters precedes shrinkage in macroprolactinomas, and if not seen within days of treatment may indicate DA resistance requiring early surgery.

Original languageEnglish
Pages (from-to)261-266
Number of pages6
JournalPituitary
Volume10
Issue number3
DOIs
Publication statusPublished - Sep 2007
Externally publishedYes

Fingerprint

Prolactinoma
Dopamine Agonists
Magnetic Resonance Imaging
Healthy Volunteers
Hyperprolactinemia
Prolactin
Blood Vessels
Therapeutics
Neoplasms
Capillary Permeability
Oral Contraceptives
Adenoma
Volunteers
Permeability

Keywords

  • Dopamine agonist (DA)
  • Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)
  • Prolactinoma

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). / Manuchehri, Alireza M.; Sathyapalan, Thozhukat; Lowry, Martin; Turnbull, Lindsay W.; Rowland-Hill, Christopher; Atkin, Stephen.

In: Pituitary, Vol. 10, No. 3, 09.2007, p. 261-266.

Research output: Contribution to journalArticle

Manuchehri, Alireza M. ; Sathyapalan, Thozhukat ; Lowry, Martin ; Turnbull, Lindsay W. ; Rowland-Hill, Christopher ; Atkin, Stephen. / Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). In: Pituitary. 2007 ; Vol. 10, No. 3. pp. 261-266.
@article{554dd98adccf4b059111eab6add1faa2,
title = "Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)",
abstract = "Context: Dopamine agonists (DA) may act on prolactinoma size and secretion through additional effects on adenoma vascularity that can be visualized using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Objective: We hypothesized that DAs may exert their effect through a change in tumour functional vascularity leading to a reduction of prolactin (PRL) levels and tumour size. Subjects and methods: To investigate this, 23 subjects were studied comprising five with macroprolactinomas, 11 with microprolactinomas, seven with non-lesion hyperprolactinemia and 15 normal volunteers (including five females on oral contraceptive pills). Patients with macroprolactinomas were treated with cabergoline 4 mg weekly and microprolactinomas were treated with quinagolide 75 μg daily for the duration of study. DCE-MRI was performed immediately pre-treatment and at 3-4 days, 1 and 3-4 months after treatment. Normal volunteers took three 75 μg quinagolide doses and were scanned pre-treatment and at 3 days. Data were analysed using the Brix model, producing a measure of vascular permeability and leakage space. Results: PRL levels were significantly reduced in all patients and volunteers. Vascular parameters decreased significantly for four of five macroprolactinomas and all microprolactinomas which were maintained during the treatment period (p < 0.01). No changes were seen in normal volunteers or non-lesion hyperprolactinemia. One of five macroprolactinomas showed no change in either permeability or tumour size. Conclusion: Functional prolactinoma vascularity differs from non-lesion hyperprolactinemic pituitary and normal pituitary, and is responsive to DA therapy. The reduction in vascular parameters precedes shrinkage in macroprolactinomas, and if not seen within days of treatment may indicate DA resistance requiring early surgery.",
keywords = "Dopamine agonist (DA), Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), Prolactinoma",
author = "Manuchehri, {Alireza M.} and Thozhukat Sathyapalan and Martin Lowry and Turnbull, {Lindsay W.} and Christopher Rowland-Hill and Stephen Atkin",
year = "2007",
month = "9",
doi = "10.1007/s11102-007-0048-4",
language = "English",
volume = "10",
pages = "261--266",
journal = "Pituitary",
issn = "1386-341X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Effect of dopamine agonists on prolactinomas and normal pituitary assessed by dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)

AU - Manuchehri, Alireza M.

AU - Sathyapalan, Thozhukat

AU - Lowry, Martin

AU - Turnbull, Lindsay W.

AU - Rowland-Hill, Christopher

AU - Atkin, Stephen

PY - 2007/9

Y1 - 2007/9

N2 - Context: Dopamine agonists (DA) may act on prolactinoma size and secretion through additional effects on adenoma vascularity that can be visualized using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Objective: We hypothesized that DAs may exert their effect through a change in tumour functional vascularity leading to a reduction of prolactin (PRL) levels and tumour size. Subjects and methods: To investigate this, 23 subjects were studied comprising five with macroprolactinomas, 11 with microprolactinomas, seven with non-lesion hyperprolactinemia and 15 normal volunteers (including five females on oral contraceptive pills). Patients with macroprolactinomas were treated with cabergoline 4 mg weekly and microprolactinomas were treated with quinagolide 75 μg daily for the duration of study. DCE-MRI was performed immediately pre-treatment and at 3-4 days, 1 and 3-4 months after treatment. Normal volunteers took three 75 μg quinagolide doses and were scanned pre-treatment and at 3 days. Data were analysed using the Brix model, producing a measure of vascular permeability and leakage space. Results: PRL levels were significantly reduced in all patients and volunteers. Vascular parameters decreased significantly for four of five macroprolactinomas and all microprolactinomas which were maintained during the treatment period (p < 0.01). No changes were seen in normal volunteers or non-lesion hyperprolactinemia. One of five macroprolactinomas showed no change in either permeability or tumour size. Conclusion: Functional prolactinoma vascularity differs from non-lesion hyperprolactinemic pituitary and normal pituitary, and is responsive to DA therapy. The reduction in vascular parameters precedes shrinkage in macroprolactinomas, and if not seen within days of treatment may indicate DA resistance requiring early surgery.

AB - Context: Dopamine agonists (DA) may act on prolactinoma size and secretion through additional effects on adenoma vascularity that can be visualized using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Objective: We hypothesized that DAs may exert their effect through a change in tumour functional vascularity leading to a reduction of prolactin (PRL) levels and tumour size. Subjects and methods: To investigate this, 23 subjects were studied comprising five with macroprolactinomas, 11 with microprolactinomas, seven with non-lesion hyperprolactinemia and 15 normal volunteers (including five females on oral contraceptive pills). Patients with macroprolactinomas were treated with cabergoline 4 mg weekly and microprolactinomas were treated with quinagolide 75 μg daily for the duration of study. DCE-MRI was performed immediately pre-treatment and at 3-4 days, 1 and 3-4 months after treatment. Normal volunteers took three 75 μg quinagolide doses and were scanned pre-treatment and at 3 days. Data were analysed using the Brix model, producing a measure of vascular permeability and leakage space. Results: PRL levels were significantly reduced in all patients and volunteers. Vascular parameters decreased significantly for four of five macroprolactinomas and all microprolactinomas which were maintained during the treatment period (p < 0.01). No changes were seen in normal volunteers or non-lesion hyperprolactinemia. One of five macroprolactinomas showed no change in either permeability or tumour size. Conclusion: Functional prolactinoma vascularity differs from non-lesion hyperprolactinemic pituitary and normal pituitary, and is responsive to DA therapy. The reduction in vascular parameters precedes shrinkage in macroprolactinomas, and if not seen within days of treatment may indicate DA resistance requiring early surgery.

KW - Dopamine agonist (DA)

KW - Dynamic contrast enhanced magnetic resonance imaging (DCE-MRI)

KW - Prolactinoma

UR - http://www.scopus.com/inward/record.url?scp=35848930579&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35848930579&partnerID=8YFLogxK

U2 - 10.1007/s11102-007-0048-4

DO - 10.1007/s11102-007-0048-4

M3 - Article

VL - 10

SP - 261

EP - 266

JO - Pituitary

JF - Pituitary

SN - 1386-341X

IS - 3

ER -